Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06165341 · ClinicalTrials.gov registry record · Phase 3
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
A Phase 3 study of Alpha1-Antitrypsin Deficiency, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 50
- Enrollment target
- 20
- Study locations
NCT06165341 is a Phase 3 study of Alpha1-Antitrypsin Deficiency that is actively recruiting participants, run by Takeda. The registered enrollment target is 50 participants, below the 150-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06165341, a Phase 3 study of Alpha1-Antitrypsin Deficiency, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 50 participants
- Enrollment target
- 20
- Study locations
Study Summary
The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver cells, which leads to liver problems such as liver scarring (fibrosis), continuing liver damage (cirrhosis), and eventually end stage liver disease. Fazirsiran is a medicine that reduces the creation of the Z-AAT protein and thus the build-up of this abnormal protein in the liver. People with this type of liver disease who already have mild liver scarring will take part in the study. They will be treated with fazirsiran or a placebo for about 2 years. This study will check the long-term safety of fazirsiran, whether participants tolerate the treatment and if there are any effects on liver scarring. A liver biopsy, a way of collecting a small tissue sample from the liver, will be taken twice during the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fazirsiran Injection
Study Locations (20)
Arizona
- St Joseph's Hospital and Medical Center - Phoenix
- Mayo Clinic - PPDS - Phoenix
- University of Arizona Thomas D. Boyer Liver Institute - Tucson
California
- University of California San Diego - La Jolla
- UCLA Pulmonary and Critical Care - Los Angeles
- University of California Benioff Children's Hospital - San Francisco
Michigan
- University of Michigan Hospital - 1500 E Medical Center Dr - Ann Arbor
- Henry Ford Health System - Novi
New York
- NYU Langone Medical Center - New York
- Columbia University Irving Medical Center - New York
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Florida
- Schiff Center for Liver Diseases/University of Miami - Miami
Indiana
- Indiana University School of Medicine-Indianapolis - Indianapolis
Iowa
- University Of Iowa Hospitals And Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2028-08-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06165341
The ClinicalTrials.gov registry entry for NCT06165341 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 150-participant average among 5 other Alpha1-Antitrypsin Deficiency trials with a reported enrollment target (67% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alpha1-Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06165341 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Arizona, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06165341 about?
NCT06165341 is a clinical study titled "Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)". The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of the AAT protein, called Z-AAT. Making an abnormal version of the AAT protein can result in liver disease as Z-AAT builds up in liver ce...
What is the current status of trial NCT06165341?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 50 participants. The study started on 2024-03-01. Estimated completion is 2028-08-26.
What conditions does trial NCT06165341 study?
This clinical trial studies the following conditions: Alpha1-Antitrypsin Deficiency.
What interventions are being tested in trial NCT06165341?
The interventions under investigation include: Placebo (DRUG), Fazirsiran Injection (DRUG).
Who is sponsoring clinical trial NCT06165341?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06165341 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha1-Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
RECRUITING · Phase 3
-
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
RECRUITING
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
COMPLETED · Phase 1
-
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.